Navigation Links
Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
Date:8/1/2013

lozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Halozyme Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning our product candidates in development, potential benefits and attributes of rHuPH20 and our product candidates including safety and clinical profile, anticipated clinical and regulatory events and our intended actions, that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are usually (but not always) identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning.  Actual results could differ materially from the expectations contained in forward-looking statements as a result of risks and uncertainties including clinical trial enrollment and results, regulatory approval requirements, unexpected expenditures and costs, unexpected results or delays in development and regulatory review, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2013. Halozyme does not undertake to
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Halozyme to Host Second Quarter 2013 Financial Results Conference Call
2. Halozymes Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
3. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
4. Halozyme Reports First Quarter 2013 Financial Results
5. Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
6. Halozyme Therapeutics Names Matt Posard to Board of Directors
7. Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
8. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
9. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
10. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
11. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... RadiologyAuction will have their first auction starting May ... at the end of the auction on May 27 ... Fuji Cr,s, Agfa and Sony, printers and GE portable ... imaging equipment will be available at later auctions each ... of buying and selling imaging equipment, the brokers at ...
(Date:5/4/2015)... 2015  Oncobiologics, Inc., a biotherapeutics company focused ... has completed the construction of its GMP commercial ... Cranbury, New Jersey . ... designed to utilize multiple technologies that enable rapid ... the use of the latest single-use technologies, the ...
(Date:5/4/2015)... 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... HealthCare (Bayer) to develop and commercialize ISIS-FXI Rx ... the agreement, Isis is eligible to receive up to ... million up-front payment and a $55 million payment upon ... in patients with compromised kidney function. Isis is also ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5
(Date:5/4/2015)... McNeil & Company , a ... of coverage for its Emergency Services Insurance Program ... insurance and proactive risk management to the emergency services ... to providing our customers with unparalleled service and the ... We are excited to launch over 100 new enhancements ...
(Date:5/4/2015)... Orange, NJ (PRWEB) May 04, 2015 ... non-profit organization devoted exclusively to funding innovative lymphoma research ... of education programs, outreach initiatives and patient services – ... at the historic Mayfair Farms in West Orange, NJ ... raised nearly $500,000 for innovative research programs through LRF. ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 METTLER ... The Importance of Data Integrity in a GXP ... as guest presenter. This webinar will be presented ... GMT). , Data integrity is a critical component ... to regulatory agencies. However, in recent years an ...
(Date:5/4/2015)... WA (PRWEB) May 04, 2015 EyeCRO ... a collaboration to facilitate development of NM108, a first-in-class ... that lead to blindness, including Diabetic Retinopathy. The ... platform developed by EyeCRO, which can deliver drugs to ... topical eyedrop. , Under the terms of the ...
(Date:5/4/2015)... Greensboro, NC (PRWEB) May 04, 2015 ... excited to offer this unique program to other leadership ... create valuable ties between CCL and successful practitioners, expanding ... organizations around the globe,” said John R. Ryan, CCL ... consultancy joins the CCL Partner Network , it ...
Breaking Medicine News(10 mins):Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:METTLER TOLEDO Announces Live Webinar on the Importance of Data Integrity in a GXP Regulated Laboratory 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2
... Amsterdam, The Netherlands: Only 35% of anaesthesiologists are carrying ... make a significant impact on how well patients recover ... (Sunday 12 June) at the European Anaesthesiology Congress in ... and US anaesthesiologists found that although more than 95% ...
... bleeding was higher in the most commonly implanted heart device ... Henry Ford Hospital in Detroit. The HeartMate II, a ... connected to the patient,s heart that takes over the pumping ... were more instances of bleeding in the skull and gastrointestinal ...
... -- Baseline concussion tests for athletes may do more harm ... concussion testing provides a baseline score of an athlete,s cognitive ... Athletes who suffer a concussion retake the test, and if ... typically banned from play until their score improves. But ...
... By Maureen Salamon HealthDay Reporter , FRIDAY, June ... be tied to better sex? That,s the finding ... adults against their reports of satisfaction in the bedroom. ... studied data from more than 3,200 men and women ages ...
... , FRIDAY, June 10 (HealthDay News) -- Urban development ... says. The study, led by researchers at ... that the sprawl of strip malls and other paved ... air quality during the summer months. In conducting ...
... and Afghanistan veterans who visited a VA integrated care ... health and social work evaluations than veterans who visited ... study led by a San Francisco VA Medical Center ... veterans, younger veterans, veterans with mental health diagnoses, and ...
Cached Medicine News:Health News:Important monitoring of heart performance is omitted in two-thirds of high-risk surgical operations 2Health News:Important monitoring of heart performance is omitted in two-thirds of high-risk surgical operations 3Health News:Internal bleeding higher with popular heart device than earlier model 2Health News:Validity of Baseline Concussion Tests Questioned 2Health News:Self-Confidence, Empathy May Make for Better Sex 2Health News:Self-Confidence, Empathy May Make for Better Sex 3Health News:City Pavement Affects Weather, Boosting Smog: Study 2Health News:'1-stop' clinic ups mental health, social work visits for veterans 2Health News:'1-stop' clinic ups mental health, social work visits for veterans 3
... VersaPulse PowerSuite holmium laser combines excellent ... precise, virtually bloodless procedures. It is ... and gall bladder stones of all ... surgical tool. Because its laser light ...
... VersaPulse PowerSuite holmium laser combines excellent ... precise, virtually bloodless procedures. It is ... and gall bladder stones of all ... surgical tool. Because its laser light ...
... capability to quickly deliver up to 250 ... for powerful single-pulse ablation. This type of ... coldest and cleanest CO2 surgical laser available ... with the independent adjustment of pulse energy ...
... technology has allowed for perfecting mini-invasive endoscopic ... various pathologies with a considerable social impact. ... reducing the post-operatory times and represents a ... in all hospital structures.,DEKAs family of Nd:YAG ...
Medicine Products: